(Q73394947)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11156735%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

Loss of heterozygosity at 1p, 8p, 10p, 13q, and 17p in advanced urothelial cancer and lack of relation to chemotherapy response and outcome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11156735%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

1 reference

L Sengeløv

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11156735%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M Christensen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11156735%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

H D von der Maase

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11156735%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

T Horn

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11156735%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

N Marcussen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11156735%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

C Kamby

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11156735%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

T Orntoft

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11156735%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 December 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11156735%20AND%20SRC:MED&resulttype=core&format=json

Cancer Genetics and Cytogenetics

3 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11156735%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

123

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11156735%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11156735%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

109-113

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11156735%20AND%20SRC:MED&resulttype=core&format=json

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Molecular alterations in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Localization of tumor suppressor gene associated with distant metastasis of urinary bladder cancer to a 1-Mb interval on 8p22

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Platinum analogue combination chemotherapy: cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced B

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Evidence of a hereditary p53 syndrome in cancer-prone families

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Correlation of allelic loss of the P53 gene and tumor grade, stage, and malignant progression in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Accumulated allelic losses in the development of invasive urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Retinoblastoma gene mutations in primary human bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

The relevance of p53 mutation in urological malignancies: possible clinical implications for bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

p53 overexpression as a prognostic factor for advanced stage bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Accumulation of nuclear p53 and tumor progression in bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

p53 mutations have no additional prognostic value over stage in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

p53 and treatment of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-4608%2800%2900308-3

7 January 2021

10.1016/S0165-4608(00)00308-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11156735%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference